Robert Dempsey

Robert Dempsey currently serves as the Chief Executive Officer and President of AsclepiX Therapeutics, Inc. since March 2021, and as the Chair of the Board of Directors at TearSolutions Inc. starting December 2023. Dempsey also holds positions as a Board Director at Neurotech Pharmaceuticals, Inc. since July 2022 and Glauconix Biosciences, Inc. since October 2019, and as the Chair of the Board of Directors for iVeena and the Holland Foundation For Sight Restoration. Previously, Dempsey led TearClear as Chief Executive Officer and held significant roles at Shire, including Group Vice President for the Global Ophthalmics Franchise and Vice President for Eye Care, where responsibilities included the commercialization strategy for Dry Eye and the international expansion of ophthalmic products. With over 23 years of leadership experience in Eye Care, Dempsey's expertise covers medical and scientific affairs as well as commercial management. Education includes an MBA and a Bachelor's in Healthcare Marketing from Northeastern University.